The atherogenic index of plasma complicates the thrombotic tendency of chronic myeloproliferative disorders: A retrospective cohort study

Yıl 2023, , 54 - 61, 29.04.2023

Mine Karadeniz , Ozge Ozcan Abacıoglu , Ümit Yavuz Malkan , İbrahim Celaleddin Haznedaroğlu

https://doi.org/10.56016/dahudermj.1249255

Öz

Objectives: Chronic myeloproliferative diseases (CMPD) are neoplastic disorders leading to hypercoagulability and thrombosis. The critical hemostatic abnormalities include alterations in the blood viscosity and a history of recent thrombus. The aim of this study is to assess the interrelationships among the atherogenic index of plasma (AIP) and thromboembolism of CMPD with JAK2 V617F mutation.
Methods: Ninety-two patients diagnosed as CMPD with JAK2 V617F mutation and 73 controls were included into the study. The patients were evaluated for the presence of any venous or arterial thromboembolic events. AIP was calculated by using the formula log (Tg/HDL) from serum triglyceride and high-density lipoprotein values.
Results: The study group consisted of 30 patients (33%) with myelofibrosis (MF), 42 patients (46%) with polycythemia vera (PV) and 20 patients (21%) with essential thrombocythemia (ET). Two study groups were similar in terms of sex, age and other comorbidities (p > 0.05). CMPD group had higher levels of right blood cell count (RBC), red blood cell distribution width (RDW), platelets (PLT), hemotocrit (Hct) and AIP. Univariate and multivariate logistic regression analysis revealed that platelet count, RBC and AIP were independent predictors for thrombosis in both groups. The comparison of ROC curve analysis disclosed that AIP was superior to platelet count and RBC in predicting thrombosis.
Conclusion: AIP can be used to determinate higher risk of thromboembolism in patients with CMPD. As a reliable and ‘easy-to-assess’ diagnostic tool, AIP could be useful for the determination of thrombotic events in CMPD clinicobiological disease course.

Anahtar Kelimeler

atherogenic index, myeloproliferative, Janus kinase, thromboembolism

Kaynakça

• Bittencourt RI, Vassallo J, Chauffaille Mde L, Xavier SG, Pagnano KB, Nascimento AC, et al. Philadelphia-negative chronic myeloproliferative neoplasms. Rev Bras Hematol Hemoter. 2012;34(2):140-9.
• Uysal A, ALTINER Ş, Çelik S, Uysal S, Çebi AH. Genetic analysis of BCR-ABL negative chronic myeloproliferative diseases at initial diagnosis and their clinical effects. Cukurova Medical Journal. 2020;45(3):933-9.
• Azevedo AP, Silva SN, Reichert A, Lima F, Júnior E, Rueff J. Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population. Biomed Rep. 2017;7(4):370-6.
• Kahraman CY, Sincan G, Tatar A. Evaluation of the Relationship between Janus Kinase 2 Mutational Burden and Clinical Findings in Adult Myeloproliferative Neoplasm Patients. Medical Bulletin of Haseki/Haseki Tip Bulteni. 2022;60(1).
• de Lacerda JF, Oliveira SN, Ferro JM. Chronic myeloproliferative diseases. Handb Clin Neurol. 2014;120:1073-81.
• Soyer N, Haznedaroğlu İ C, Cömert M, Çekdemir D, Yılmaz M, Ünal A, et al. Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. Turk J Haematol. 2017;34(1):27-33.
• Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122(13):2176-84.
• Byrnes JR, Wolberg AS. Red blood cells in thrombosis. Blood. 2017;130(16):1795-9.
• Kuznetsova PI, Raskurazhev AA, Shabalina AA, Melikhyan AL, Subortseva IN, Tanashyan MM. Red Blood Cell Morphodynamics in Patients with Polycythemia Vera and Stroke. Int J Mol Sci. 2022;23(4).
• Geringer J, Fenderson J, Osswald M. Essential Thrombocythemia Complicated by Occlusive Thrombosis of the Abdominal Aorta. Case Rep Hematol. 2019;2019:9454501.
• Jung SM, Jun H. Recurrent thrombosis of splanchnic and lower extremity arteries with essential thrombocythemia. SAGE Open Med Case Rep. 2019;7:2050313x19880079.
• Cai G, Liu W, Lv S, Wang X, Guo Y, Yan Z, et al. Gender-specific associations between atherogenic index of plasma and the presence and severity of acute coronary syndrome in very young adults: a hospital-based observational study. Lipids Health Dis. 2019;18(1):99.
• Dobiásová M. Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications. Clin Chem. 2004;50(7):1113-5.
• Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128(3):275-90.
• Harrison CN. Platelets and thrombosis in myeloproliferative diseases. Hematology Am Soc Hematol Educ Program. 2005:409-15.
• Hobbs CM, Manning H, Bennett C, Vasquez L, Severin S, Brain L, et al. JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood. 2013;122(23):3787-97.
• Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3):840-6.
• Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120(25):4921-8.
• Tremblay D, Vogel AS, Moshier E, Hoffman R, Kremyanskaya M, Zhou S, et al. Outcomes of splanchnic vein thrombosis in patients with myeloproliferative neoplasms in a single center experience. Eur J Haematol. 2020;104(1):72-3.
• Ageno W, Riva N, Schulman S, Beyer-Westendorf J, Bang SM, Senzolo M, et al. Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry. JAMA Intern Med. 2015;175(9):1474-80.
• Matsuura S, Thompson CR, Belghasem ME, Bekendam RH, Piasecki A, Leiva O, et al. Platelet Dysfunction and Thrombosis in JAK2(V617F)-Mutated Primary Myelofibrotic Mice. Arterioscler Thromb Vasc Biol. 2020;40(10):e262-e72.
• Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129(6):680-92.
• Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128-33; quiz 252.
• Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5(11):e369.
• Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120(6):1197-201.
• Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-901.
• Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874-81.
• Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-70.
• Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C, et al. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol 2016 Vol. 91 Issue 4 Pages 390-4. Accession Number: 26799697 DOI: 10.1002/ajh.24293
• Yang E, Wang M, Wang Z, Y. Wang Li. X, Ming J, et al. Comparison of the effects between MPL and JAK2V617F on thrombosis and peripheral blood cell counts in patients with essential thrombocythemia: a meta-analysis. Ann Hematol 2021 Vol. 100 Issue 11 Pages 2699-2706. Accession Number: 34383101 PMCID: PMC8510937 DOI: 10.1007/s00277-021-04617-6
• Stuckey R, Ianotto JC, Santoro M, Czyż A, Perez Encinas MM, Gómez-Casares MM, et al. Validation of thrombotic risk factors in 1381 patients with essential thrombocythaemia: A multicentre retrospective real-life study. Br J Haematol 2022 Vol. 199 Issue 1 Pages 86-94 Accession Number: 35906782 DOI: 10.1111/bjh.18387
• Horvat I, Boban A, Zadro R, Antolic MR, Serventi-Seiwerth R, Roncevic P, et al. Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2019;19(1):53-63.
• Alvarez-Larrán A, Bellosillo B, Pereira A, Kerguelen A, Hernández-Boluda JC, Martínez-Avilés L, et al. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol. 2014;89(5):517-23.
• Kubong LN, Nya Biapa PC, Chetcha B, Yanou-Njintang N, Moor Ama VJ, Pieme CA. Relationship between Higher Atherogenic Index of Plasma and Oxidative Stress of a Group of Patients Living with Sickle Cell Anemia in Cameroon. Adv Hematol. 2020;2020:9864371.
• Sherief LM, Dawood O, Ali A, Sherbiny HS, Kamal NM, Elshanshory M, et al. Premature atherosclerosis in children with beta-thalassemia major: New diagnostic marker. BMC Pediatr. 2017;17(1):69.
• Liu H, Liu K, Pei L, Li S, Zhao J, Zhang K, et al. Atherogenic Index of Plasma Predicts Outcomes in Acute Ischemic Stroke. Front Neurol. 2021;12:741754.